Cowen Starts Janux Therapeutics (JANX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
BofA Securities Starts Janux Therapeutics (JANX) at Buy
July 6, 2021 8:21 AM EDTBofA Securities analyst Geoff Meacham initiates coverage on Janux Therapeutics (NASDAQ: JANX) with a Buy rating and a price target of $35.00.
The analyst commented, "We initiate coverage on Janux Therapeutics with a Buy rating and a $35 PO. Janux is an oncology-focused company... More
